Article
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics - 1 Nov 2020
Beitelshees Amber L, Stevenson James M, El Rouby Nihal, Dillon Chrisly, Empey Philip E, Fielstein Elliot M, Johnson Julie A, Limdi Nita A, Ong Henry H, Franchi Francesco, Angiolillo Dominick J, Peterson Joshua F, Rosenman Marc B, Skaar Todd C, Tuteja Sony, Cavallari Larisa H
Abstract excerpt
PURPOSE: Genotype-guided antiplatelet therapy is increasingly being incorporated into clinical care. The purpose of this study is to determine the extent to which patients initially genotyped for CYP2C19 to guide antiplatelet therapy were prescribed additional medications affected by CYP2C19. METHODS: We assembled a cohort of patients from eight sites performingCYP2C19 genotyping to inform antiplatelet therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.